Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk ...

Johnson & Johnson is a global leader in the pharmaceutical and medical device industries. Its key products include ...

Shares of Collegium Pharmaceutical COLL have gained around 12% over the past three months, driven by growing investor ...

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx ...

In the past six months, there have been 33 biotech acquisitions valued at $1 billion or more, capped by AbbVie’s acquisition ...

GNI Group Ltd. (TSE: 2160, "GNI Group” or the "Company”) today announced that it has completed the acquisition of all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by ...

Ligand Pharma (LGND) stock jumped in the final week of June, but the proximate cause was the pricing of $625M of convertible ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Three mid-cap biotechs have become prime acquisition targets, but only one offers what big pharma is hunting for most.